This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IGF1 Receptor. Cixutumumab is a monoclonal antibody for the treatment of solid tumors.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-Human IGF1 Receptor Recombinant Antibody (Cixutumumab)Recombinant monoclonal antibody to IGF1 Receptor. Cixutumumab is a monoclonal antibody for the treatment of solid tumors.
It is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABL-091 | Recombinant Anti-human IGF1R VHH Single Domain Antibody | WB, ELISA, IHC, FC, FuncS | Llama VHH |
TAB-096ZJ | Anti-Human IGF-1R Single Domain Antibody (TAB-096ZJ), Research Grade Biosimilar | ELISA, IHC, IF, WB | Single domain antibody |
HPAB-1545-FY | Recombinant Llama Anti-IGF1R Single Domain Antibody (HPAB-1545-FY) | WB, ELISA | Llama VHH |
HPAB-1546-FY | Recombinant Llama Anti-IGF1R Single Domain Antibody (HPAB-1546-FY) | WB, ELISA | Llama VHH |
HPAB-1547-FY | Recombinant Llama Anti-IGF1R Single Domain Antibody (HPAB-1547-FY) | WB, ELISA | Llama VHH |
There are currently no Customer reviews or questions for AFC-TAB-078. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.